Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Poster display session

5010 - Ongoing Phase 1 Trial of SL-801, a Novel XPO-1 Inhibitor, in Patients with Advanced Solid Tumors; Interim Results


11 Sep 2017


Poster display session


Cytotoxic Therapy;  Clinical Research


Judy Wang


Annals of Oncology (2017) 28 (suppl_5): v122-v141. 10.1093/annonc/mdx367


J. Wang1, J. Nemunaitis2, G. Chiorean3, P. Lorusso4, K. Courtney5, A. Olguin6, J. Bullington7, S. Shemesh7, J. Chen6, C. Brooks8, T.M. Bauer9

Author affiliations

  • 1 Sarah Cannon Research Institute, Florida Cancer Specialists, 34232 - Sarasota/US
  • 2 Mary Crowley Cancer Research Center, Mary Crowley Cancer Research Center, Dallas/US
  • 3 Seattle Cancer Center Alliance, University of Washington, Seattle/US
  • 4 Yale Cancer Center, Yale University, New Haven/US
  • 5 Internal Medicine, UT Southwestern Medical Center, Dallas/US
  • 6 R&d, Stemline Therapeutics, New York/US
  • 7 Clinical Operations, Stemline Therapeutics, New York/US
  • 8 R&d, Stemline Therapeutics, 10022 - New York/US
  • 9 Medical Oncology, Tennessee Oncology, Nashville/US


Abstract 5010


Exportin-1 (XPO1) is a critical nuclear export protein involved in nuclear-cytoplasmic transport and is overexpressed in multiple malignancies. SL-801 is a novel oral small molecule inhibitor of XPO1 and has shown potent in vitro and in vivo anti-tumor activity against a broad range of hematologic and solid malignancies. SL-801 has been shown to reversibly inhibit XPO1, which may translate to selective activity and potential safety benefits. Study SL-801-0115 is a first-in-human, dose-escalation study in adult patients with locally advanced, unresectable or metastatic solid tumors that are resistant to or relapsed following available standard systemic therapy. Preliminary interim results in the ongoing dose-escalation Phase 1 clinical study are reported.


The objective of this multicenter, dose-escalation phase 1 trial is to evaluate the safety and tolerability of SL-801, identify the maximum tolerated dose (MTD), and assess pharmacokinetics (PK) with increasing doses. SL-801 is administered daily on Day 1 through Day 4 and Day 8 through Day 11 every 21 days. The starting dose cohort was 5 mg and has reached 35 mg to date.


As of 3/31/17, 19 heavily pretreated (range: 1-11 prior therapies) adult patients with advanced solid tumors have received SL-801 (6 Females, 13 Males). Median age is 62 years (range: 39-75). MTD has not been reached. Median follow-up is 1.4 months (range: 0.1-4.9). Pharmacokinetic analyses are ongoing. The most frequent treatment-related Grade 1-2 AEs were fatigue and nausea (26%), diarrhea (16%), and myalgia, vomiting and decreased appetite (11% each). Grade 3 AEs, possibly treatment-related, included diarrhea (n = 1; 5 mg) and acute renal injury (n = 1; 30 mg). There were no grade 4 or 5 treatment-related events. Three patients achieved stable disease, for 3-7 cycles, by investigator assessment.


The initial dose-escalation of SL-801 appears to be well tolerated to date in patients with advanced solid malignancies. Enrollment continues in this ongoing Phase 1 trial and updated safety and efficacy data will be presented. Clinical trial information: NCT02667873.

Clinical trial identification


Legal entity responsible for the study

Stemline Therapeutics


Stemline Therapeutics


A. Olguin, J. Bullington, S. Shemesh, J. Chen: Stemline Therapeutics: employment, stock options. C. Brooks: Stemline Therapeutics: employment, stock options, patents. All other authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.